Navigation Links
Thomson Reuters Reveals New Strategies for Navigating Big Data in the Pharmaceutical Industry
Date:9/19/2013

PHILADELPHIA, Sept. 19, 2013 /PRNewswire/ --The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today released Big Data and the Needs of the Pharma Industry, a whitepaper offering new strategies for managing Big Data, most specifically by using an array of technologies to convert it into more meaningful, accessible Little Data. The paper highlights how the inherently data-driven pharmaceutical industry requires deep, broad information to feed drug R&D, but the way it processes Big Data is unique.

"The Big Data opportunity in pharma means linking a variety of content across silos," said Tim Miller, vice president of Thomson Reuters Life Sciences. "Thomson Reuters is focused on making that content work at a human level, we use ontologies and analytics to turn Big Data into actionable Little Data."

The whitepaper addresses the concept that innovation in information processing involves creating environments where data has a relevant and accessible flow. It requires the ability to break down the walls between internal, external, public and commercial content and give customers the tools they need to work across them. Solutions from Thomson Reuters, Accelrys, DataSift, Entagen, and GenoSpace shed light on the burgeoning business of converting Big Data into actionable Little Data.

Thomson Reuters Life Sciences analysts and experts explore the evolution of Big Data in pharma and the industry's current needs. The findings are based on a recent Thomson Reuters survey conducted with a group of pharmaceutical IT experts to determine the challenges and opportunities Big Data presents. Respondents overwhelmingly agreed that drug discovery and market understanding were the two greatest opportunities for the industry. They also agreed that the biggest challenge of Big Data is its manageability and how to connect data from various internal and external places to feed the innovation process.

The whitepaper also includes perspectives of industry leaders who outline new problems and opportunities. They discuss how the use of Thomson Reuters ontologies can effectively convert vast amounts of data into smaller, meaningful content. For example, one organization with which the authors collaborated was DataSift, to analyze the use of social media for drug information sharing, enabling companies to find unmet needs, new adverse events and patient reaction information.

The increased focus on personalized medicine has presented its own obstacles regarding Big Data, as the amount of genomic information increases, along with the storage, management and security of the associated content. In the whitepaper, John Quackenbush, CEO of GenoSpace, an information architecture company focused on genomic medicine, discusses issues of concern in precision medicine and how the transformation of Big Data to Little Data plays a pivotal role in addressing them.

Read the whitepaper: Big Data and the Needs of the Pharma Industry

Follow Cortellis (@Cortellis) on Twitter for the latest news in drug discovery, development, regulatory, commercialization, forecast and generics intelligence.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
2. Thomson Reuters Finds Increase in New Research for Neglected Tropical Diseases
3. Thomson Reuters Speeds Regulatory Decision Making with New Pharmaceutical Intelligence Solution
4. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
5. Thomson Reuters Welcomes Inova Software to Its Partner Ecosystem for Life Sciences
6. Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets
7. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
8. Thomson Reuters Spotlights the Impact of Personalized Medicine on Pharmaceutical R&D
9. Thomson Reuters Collaborates with One Mind for Research to Advance Traumatic Brain Injury Knowledge
10. Thomson Reuters Life Sciences Cortellis Competitive Intelligence Reaches Content Milestones
11. GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
Breaking Medicine News(10 mins):